Neurotrope Inc (NASDAQ:NTRP) shares slipped 23.78% to $5.80 and were unchanged in after-hours trading. Share prices have been trading in a 52-week range of $5.55 to $29.00. The company has a market cap of $46.12 million at 7.89 million shares outstanding.
This week, Neurotrope Inc presented clinical results from its recently completed Phase 2 trial demonstrating that moderate-to-severe Alzheimer’s disease patients treated with 20 µg bryostatin-1 showed preliminary evidence of sustained improvement in cognition compared to placebo.
“In this exploratory study evaluating a novel mechanism of action, we see an encouraging therapeutic signal in late stage AD patients with the 20 µg group, which was maintained across time points with relatively minimal toxicity and good tolerability,” said Martin R. Farlow, MD, Vice Chairman for Research in the Department of Neurology, Indiana University School of Medicine, Indiana Alzheimer Disease Center, who presented the data.
“This study has shown a real and sustained increase in SIB over and above standard of care in a difficult to treat population. It is important now to determine if these effects can be maintained and enhanced over a longer period of time,” he continued.
“Although the study was not powered for statistical significance at a = 0.05, the clinical effects in the 20 µg group compared to placebo were consistent in magnitude for cognition and function, and hold up under multiple sensitivity analyses,” said Suzanne Hendrix, PhD of Pentara Corporation.
Neurotrope Inc is a biopharmaceutical company with its product candidates in pre-clinical and clinical development. The company is focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer’s disease, which is in the clinical testing stage.
Bryostatin, which is a protein kinase C Alpha and e activator, is also developed for other neurodegenerative or cognitive diseases and dysfunctions, which are in pre-clinical testing. Its second generation PKC activators, such as the Bryologs are meant for the treatment of central nervous system disorders, lysosomal storage diseases, stroke, cardio protection and traumatic brain injury. It develops Bryostatin-1 for the treatment of Alzheimer’s disease along with the rare (Orphan) diseases, such as Fragile X Syndrome and Niemann-Pick Type C. It has completed Phase IIa clinical trials of Bryostatin-1 for the treatment of patients presented clinical results from its recently completed Phase 2 trial demonstrating that moderate-to-severe Alzheimer’s diseasewith AD.